Study designs of evaluations included in the review
All published randomised controlled trials (RCTs) of nifedipine in the secondary prevention of CHD for which mortality data were available, were included.
Specific interventions included in the review
Nifedipine at doses of 30, 40, 50, 60, 80 and 100 mg/day, to a maximum of 120 mg.
Participants included in the review
Patients with coronary heart disease (CHD). Of the 16 studies included, 12 included patients with myocardial infarction (MI), 3 included patients with unstable angina and 1 included patients with stable angina, with and without a history of prior infarction.
Total number of participants involved was 4,171 (control group, n=4,183).
Outcomes assessed in the review
Mortality was assessed.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the authors performed the selection.